Karl A. Nath - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Karl A. Nath's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Karl A. Nath
Verified
Editor-In-Chief, Mayo Clinic Proceedings
Rochester
Beats
bipolar disorder,Mental health mental health tech, family approaches to mental health complex relationships, schizophrenia
Content
By Karl A. Nath Verified| Mayo Clinic Proceedings Verified This month’s feature highlights three articles that appear in the current issue of Mayo Clinic Proceedings. These articles are also featured on the Mayo Clinic Proceedings’ YouTube Channel (https://youtu.be/vx5MIZ-Br2s). Efficacy of Tirzepatide in Reducing Body Weight in Overweight Type 1 DiabeticsAnti-obesity medications such as tirzepatide, a glucose-dependent insulinotropic polypeptide and a glucagon-like peptide-1 dual agonist, represent a major therapeutic advancement.
By Karl A. Nath Verified| Mayo Clinic Proceedings Verified These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
By Karl A. Nath Verified| Mayo Clinic Proceedings Verified This month’s feature highlights three articles that appear in the current issue of Mayo Clinic Proceedings. These articles are also featured on the Mayo Clinic Proceedings’ YouTube Channel (https://youtu.be/vx5MIZ-Br2s). Efficacy of Tirzepatide in Reducing Body Weight in Overweight Type 1 DiabeticsAnti-obesity medications such as tirzepatide, a glucose-dependent insulinotropic polypeptide and a glucagon-like peptide-1 dual agonist, represent a major therapeutic advancement.
Company Info
Mayo Clinic Proceedings
Rochester, United States